System for treating eye and nerve diseases in diabetic and non-diabetic patients

• US 6,967,191 B2
• Filed: 03/19/2003
• Issued: 11/22/2005
• Est. Priority Date: 06/16/2000
• Status: Expired due to Term

• Current Assignee: Thomas T. Aoki
• Original Assignee: Thomas T. Aoki
• Inventors: Aoki, Thomas T.
• Primary Examiner(s): Campell, Bruce R.
• Assistant Examiner(s): TELLER, ROY R
• Application Number:
  US10/393,273
• Publication Number:
  US 20030181357A1
• Time in Patent Office: 979 Days
• Field of Search: 514/4, 514/3
• US Class Current: 514/6.5
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: Y10S 530/849 Eyes; vessels; umbilical cord

Abstract

The present invention is a system capable of increasing retinal and neural glucose oxidation by enhancing pyruvate dehydrogenase activity and therefore treats retinopathy and central nervous system disorders in both diabetic and non-diabetic patients. The current invention is a system of the treating of eye and nerve diseases using insulin pulses to a patient utilizing Chronic Intermittent Intravenous Insulin Therapy to achieve an increase in retinal and neural glucose oxidation by enhancing pryuvate dehydrogenase activity, therefore treating retinopathy and central nervous system disorders in both diabetic and non-diabetic patients.

Claims

1. A system for treating eye and nerve diseases associated with a diminution in glucose oxidation in patients through an intravenous site administering a pulse of insulin to a patient comprising:

a) determining a respiratory quotient of the patient,

b) having the patient consume a liquid or food containing glucose

c) administering intravenously the pulse of insulin at a regular interval of time until the respiratory quotient is 0.90 or greater.

2. The system of claim 1, wherein the intravenous site further comprises a needle or catheter located in the patient'"'"'s body, hand or forearm.

3. The system of claim 1, wherein the liquid or food contains 60 to 100 grams of glucose.

4. The system of claim 1, wherein the administered by the pulse of insulin is an intravenous infusion device.

5. The system of claim 1, wherein the interval of time is about six minutes.

6. The system of claim 1, wherein the pulse of insulin is tailored to achieve increased retinal and neural glucose oxidation by enhanced pyruvate dehydrogenase complex activity.

7. The system of claim 1, wherein the intravenous site is converted to a heparin or a saline lock during the rest period.